Congenital Muscular Dystrophy Clinical Trials

2 recruiting

Frequently Asked Questions

Common questions about Congenital Muscular Dystrophy clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting
Not Applicable

Modifying Factors in Striated Muscle Laminopathies

LaminopathiesEmery Dreifuss Muscular Dystrophy 2LMNA-Related Congenital Muscular Dystrophy+1 more
Institut National de la Santé Et de la Recherche Médicale, France40 enrolled8 locationsNCT05394506
Recruiting

Swiss Registry for Neuromuscular Disorders

DMDSMABMD+2 more
University of Bern2,000 enrolled19 locationsNCT05102916
Recruiting

Characterization of the Natural History of LAMA2-RD and Identification of Novel Disease Biomarkers

LAMA2-MD (Merosin Deficient Congenital Muscular Dystrophy, MDC1A)
Università Vita-Salute San Raffaele45 enrolled1 locationNCT07125040
Recruiting
Not Applicable

Assessments in Patients With Muscular Pathology and in Control Subjects : The ActiLiège Next Study

Duchenne Muscular DystrophyFascioscapulohumeral Muscular DystrophyCentronuclear Myopathy+3 more
Centre Hospitalier Universitaire de Liege300 enrolled8 locationsNCT05982119
Recruiting

Spanish Natural History Study for LAMA2 Muscular Dystrophy

Cohort StudiesMuscular DystrophiesLAMA2-MD (Merosin Deficient Congenital Muscular Dystrophy, MDC1A)+2 more
Hospital Universitari Vall d'Hebron Research Institute100 enrolled1 locationNCT06924125
Recruiting

Natural History Study of Children With LAMA2-related Dystrophies

Merosin Deficient Congenital Muscular Dystrophy
Institut de Myologie, France40 enrolled4 locationsNCT06354790
Recruiting

Congenital Muscle Disease Study of Patient and Family Reported Medical Information

Congenital Muscular Dystrophy With ITGA7 (Integrin Alpha-7) DeficiencyAlpha-Dystroglycanopathy (Congenital Muscular Dystrophy and Abnormal Glycosylation of Dystroglycan With Severe Epilepsy)Alpha-Dystroglycanopathy (Congenital Muscular Dystrophy With Fatty Liver and Infantile-onset Cataract Caused by TRAPPC11 Mutations)+1 more
Cure CMD4,000 enrolled1 locationNCT01403402